Pegloxenatide
Highest phase reached
Phase 1
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Protein
- Drug name
- Pegloxenatide
- peg 40 kd loxenatide
- peg loxenatide
- Peg loxenatide
- Peg-40 kd-loxenatide
- pegloxenatide
- Pegloxenatide
- pegloxenatide [INN]
- pegloxenatide inn
- pex 168
- PEX-168
- pex168
- Pex168
- PEX168
- PEX168(100µg)
- PEX168(200µg)
- poly oxy 1 2 ethanediyl alpha hydro omega methoxy 39 39 diester with l histidyl d alanyl l alpha glutamylglycyl l threonyl l phenylalanyl l threonyl l seryl l alpha aspartyl l leucyl l seryl l lysyl l glutaminyl l norleucyl l alpha glutamyl l alpha glutamyl l alpha glutamyl l alanyl l valyl l arginyl l leucyl l phenylalanyl l isoleucyl l alpha glutamyl l tryptophyl l leucyl l lysyl l glutaminylglycylglycyl l prolyl l seryl l serylglycyl l alanyl l prolyl l prolyl l prolyl s 1 3 2 2s 2 6 bis carboxyamino 1 oxohexyl amino ethyl amino 3 oxopropyl 2 5 dioxo 3 pyrrolidinyl l cysteinamide
- POLY(OXY-1,2-ETHANEDIYL), .ALPHA.-HYDRO-.OMEGA.-METHOXY-, 39,39-DIESTER WITH L-HISTIDYL-D-ALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-NORLEUCYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-VALYL-L-ARGINYL-L-LEUCYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-TRYPTOPHYL-L-LEUCYL-L-LYSYL-L-GLUTAMINYLGLYCYLGLYCYL-L-PROLYL-L-SERYL-L-SERYLGLYCYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-S-(1-(3-((2-(((2S)-2,6-BIS(CARBOXYAMINO)-1-OXOHEXYL)AMINO)ETHYL)AMINO)-3-OXOPROPYL)-2,5-DIOXO-3-PYRROLIDINYL)-L-CYSTEINAMIDE
- CAS registry numbers
- 2420483-82-3
- ChEMBL ID
- CHEMBL4802213
- FDA ingredient codes (UNII)
- BS678C7JWM
- First in class
- No
- Orphan designation
- No
- Drug name stem
- peg-; -tide
Investigated indications
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006096
- Highest recorded phase
- 2
- NCT01965496
- NCT01976858
- NCT02447601
- NCT02467790
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (49)
- A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women
- A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
- A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
- A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
- A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
- A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
- A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
- A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
- A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)
- A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
- AEF0217 in Participants With Down Syndrome
- An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
- Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
- Clinical Study of the Effectiveness, Tolerability and Safety of the Drug "Anti-spike, Gel, 100 g in Bottles in Package No. 1" Produced by the Republican Unitary Enterprise "Unitekhprom BSU", With a Single Intraperitoneal Use After Surgery in Adult Patients With Acute Phlegmonous Appendicitis
- Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes
- Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
- Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
- DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
- Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
In development for (1)
- Type 2 diabetes mellitus Phase 1